Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

BACKGROUND: Natural killer/T-cell lymphoma (NKTCL) is a disease with limited treatment options and poor outcomes. Daratumumab monotherapy demonstrated clinical activity in a single-patient case report. We present data from the primary analysis of a phase 2 study of daratumumab monotherapy in relapse...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Huiqiang, Zhu, Jun, Yao, Ming, Kim, Tae Min, Yoon, Dok Hyun, Cho, Seok-Goo, Eom, Hyeon Seok, Lim, Soon Thye, Yeh, Su-peng, Song, Yuqin, Kwong, Yok Lam, Kim, Jin Seok, Jin, Jie, Shi, Yuankai, Kim, HyeJin, Qing, Min, Zhou, Tianyuan, Gao, Grace, Dong, Zongqi, Qi, Ming, Kim, Won Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885403/
https://www.ncbi.nlm.nih.gov/pubmed/33588922
http://dx.doi.org/10.1186/s13045-020-01020-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885403/
https://www.ncbi.nlm.nih.gov/pubmed/33588922
http://dx.doi.org/10.1186/s13045-020-01020-y

Ejemplares similares